Table 2.

Overview of Drugs with Several Different Mechanisms of Action That Have Been Tested with the PharmaFlow Platform.

Mechanism of Action	Compound	Assay
Alkylating activity	Chlorambucil/melphalan	NE cell depletion
Nucleic acid synthesis inhibitor	Fludarabine/cytarabine	NE cell depletion
Topoisomerase inhibitor	Idarubicin/mitoxantrone	NE cell depletion
Vinca alkaloid	Vincristine/vinblastine	NE cell depletion
Corticosteroid hormone receptor agonist	Prednisolone/dexamethasone	NE cell depletion
Anti-CDx monoclonal antibody	Ofatumumab/rituximab	NE cell depletion
Proteasome inhibitor	Bortezomib/carfilzomib	NE cell depletion
HDAC inhibitor	Panobinostat/vorinostat	NE cell depletion
Hsp90 inhibitor	Tanespimycin	NE cell depletion
Farnesyltransferase inhibitor	Tipifarnib	NE cell depletion
p53-MDM2 inhibitor	Idasanutlin	NE cell depletion
BCL-2 inhibitor	Venetoclax	NE cell depletion
Multikinase inhibitor	PKC412 (midostaurin)/sorafenib	NE cell depletion
Tyrosine kinase inhibitor	Imatinib/crizotinib	NE cell depletion
AKT inhibitor	Perifosine	NE cell depletion
mTOR inhibitor	Rapamycin/everolimus	NE cell depletion
JAK1/2 inhibitor	Ruxolitinib	NE cell depletion
HIV inhibitor	Ritonavir	NE Cell depletion
FLT-3 inhibitor	Quizartinib/crenolanib	NE Cell depletion
Syk inhibitor	Entospletinib	NE Cell depletion
MEK inhibitor	Trametinib	NE Cell proliferation
PLK1 inhibitor	Volasertib	NE Cell proliferation
BTK inhibitor	Ibrutinib	NE Cell proliferation
PI3K inhibitor	Idelalisib	NE Cell proliferation
Hypomethylating activity	Decitabine/5-azacytidine	NE Cell depletion and proliferation
Immunomodulator	Thalidomide/lenalidomide	NE cell depletion and proliferation
Immune checkpoint inhibitor	Nivolumab	NE I-O
Bispecific antibodies	Blinatumomab/CD3-CD123	NE I-O